Gilead's simtuzumab fails in Phase II pancreatic cancer study
This article was originally published in Scrip
Executive Summary
Gilead Sciences reported its first set of clinical trial data for the lysyl oxidase-like-2 (LOXL2) inhibitor simtuzumab and the results were not good: simtuzumab did not improve progression-free survival (PFS) for pancreatic cancer patients in a Phase II trial.